Verve Debt Equity Ratio from 2010 to 2024

VERV Stock  USD 5.61  0.17  2.94%   
Verve Therapeutics Debt Equity Ratio yearly trend continues to be fairly stable with very little volatility. Debt Equity Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Verve Therapeutics Debt Equity Ratio regression line of quarterly data had r-squared of  0.56 and coefficient of variation of (63.23). View All Fundamentals
 
Debt Equity Ratio  
First Reported
2010-12-31
Previous Quarter
0.01700078
Current Value
0.0179
Quarterly Volatility
0.83561404
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 22.4 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 72.28, Dividend Yield of 0.0 or PTB Ratio of 1.57. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Verve Therapeutics Correlation against competitors.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Latest Verve Therapeutics' Debt Equity Ratio Growth Pattern

Below is the plot of the Debt Equity Ratio of Verve Therapeutics over the last few years. It is Verve Therapeutics' Debt Equity Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verve Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Debt Equity Ratio10 Years Trend
Slightly volatile
   Debt Equity Ratio   
       Timeline  

Verve Debt Equity Ratio Regression Statistics

Arithmetic Mean(1.32)
Coefficient Of Variation(63.23)
Mean Deviation0.71
Median(1.79)
Standard Deviation0.84
Sample Variance0.70
Range1.98
R-Value0.75
Mean Square Error0.33
R-Squared0.56
Significance0
Slope0.14
Total Sum of Squares9.78

Verve Debt Equity Ratio History

2024 0.0179
2023 0.017
2022 0.0216
2021 0.005471
2020 -1.96

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' Debt Equity Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt Equity Ratio 0.02  0.02 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.